Clovis Oncology, Inc.: Nasdaq/NYSE listing notice — Clovis Oncology to be delisted from Nasdaq on Dec 21 after Chapter 11 filing; shares to trade OTC under CLVSQ

Clovis Oncology, Inc.

Received delisting notice from Nasdaq on Dec 12, 2022 due to Chapter 11 bankruptcy petitions filed Dec 11.
Trading suspension effective at open on Dec 21; company will not appeal the determination.
Common stock expected to trade OTC beginning Dec 21 under symbol CLVSQ.
Nasdaq cited inability to sustain compliance and public interest concerns as grounds for delisting.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Clovis Oncology, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

Exchange: nasdaq
Notice: delisting notice
Rules: 5101, 5110(b), IM-5101-1

Exact text from the filing

December 12, 2022, the Company received written notice (the “ Delisting Notice ”) from the staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company’s common stock (the “ Securities ”) will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq and public interest concerns re

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-22-303183

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.